Enzyvant is a commercial-stage biotechnology company dedicated to developing novel, transformative regenerative therapies for people with devastating rare diseases. Enzyvant is a wholly-owned subsidiary of Sumitovant Biopharma Ltd. (wholly-owned by Sumitomo Dainippon Pharma Co., Ltd.) For more information about Enzyvant, visit Enzyvant.com. Follow @Enzyvant on Twitter, Facebook, and LinkedIn.

Contact Enzyvant Therapeutics
+1 617 704 9385
Visit Website